SPIDR: small-molecule peptide-influenced drug repurposing.

ABSTRACT:

Background

Conventional de novo drug design is costly and time consuming, making it accessible to only the best resourced research organizations. An emergent approach to new drug development is drug repurposing, in which compounds that have already gone through some level of clinical testing are examined for efficacy against diseases divergent than their original application. Repurposing of existing drugs circumvents the time and considerable cost of early stages of drug development, and can be accelerated by using software to screen existing chemical databases to identify suitable drug candidates.

Results

Small-molecule Peptide-Influenced Drug Repurposing (SPIDR) was developed to identify small molecule drugs that target a specific receptor by exploring the conformational b

SUBMITTER: King MD 

PROVIDER: S-EPMC5902895 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature